Skip to content
Clinical Trials – home

Azienda Ospedaliera Universitaria San Giovanni Di Dio E Ruggi d'Aragona

Research site

Italy Largo Citta' D'ippocrate 1, 84131 Salerno, Italy

  • 28 trials recruiting
  • Arteriosclerosis · Dementia Alzheimer's type · Parkinson's disease
  • Adults and children

About Specializations

Azienda Ospedaliera Universitaria San Giovanni Di Dio E Ruggi d'Aragona in Salerno, Italy specialises in clinical trials of conditions such as Arteriosclerosis, Dementia Alzheimer's type, Parkinson's disease, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology and Neurodegenerative Disorders

At Azienda Ospedaliera Universitaria San Giovanni Di Dio E Ruggi d'Aragona, the U.O.C. Neurologia is involved in research on nervous system diseases and related mental disorders, with a strong focus on conditions that affect memory, movement, and behavior.

  • Alzheimer’s disease and psychosis associated with Alzheimer’s disease, including studies aimed at improving symptom control and long-term care
  • Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy, with trials designed to slow disease progression and evaluate new therapies
  • Lewy body dementia psychosis, exploring better options for managing neuropsychiatric symptoms
  • Progressive forms of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy, focused on treatment effectiveness and safety

These studies mainly test new treatments and assess whether emerging therapies can better preserve function, reduce symptoms, and improve quality of life in patients with complex neurological conditions.

Hematology and Blood Cancers

The site has extensive activity in hemic and lymphatic diseases and neoplasms, reflecting a broad program in blood cancers and related disorders.

  • Acute myeloid leukemia, acute lymphoblastic leukemia, and Philadelphia chromosome-positive ALL, with research aimed at improving remission rates and disease control
  • Chronic lymphocytic leukemia, multiple myeloma, follicular lymphoma, and diffuse large B-cell lymphoma, evaluating more effective treatment strategies
  • Myelodysplastic syndromes and anemia linked to marrow disorders, with trials focused on transfusion needs and clinical benefit
  • Haematopoietic stem cell transplant-associated thrombotic microangiopathy, where studies aim to improve outcomes after transplant

Research in this area is centered on testing new combinations, refining treatment choices, and measuring how well therapies clear residual disease in patients with difficult-to-treat blood cancers.

Allergy, Immunology, and Autoimmune Disease

Clinical trials at this hospital in Salerno also cover a wide range of immune system diseases and inflammatory conditions, with attention to both chronic symptoms and disease activity.

  • Sjögren’s syndrome and systemic lupus erythematosus, studying therapies that may reduce inflammation and improve disease control
  • Rheumatoid arthritis, exploring better long-term management approaches
  • Hereditary angioedema and chronic spontaneous urticaria, focused on preventing attacks and reducing symptom burden
  • Systemic mastocytosis, including indolent and advanced forms, with research aimed at easing symptoms and improving safety of treatment

These studies are designed to evaluate new immune-targeted therapies, confirm safety, and help patients achieve more stable disease control over time.

Respiratory, Gastrointestinal, and Skin-Related Research

The research portfolio includes several respiratory tract diseases, digestive system diseases, and skin and connective tissue diseases, showing a broad interest in inflammatory and allergic conditions.

  • Asthma, including severe asthma and eosinophilic asthma, with trials aimed at reducing exacerbations and medication burden
  • Chronic obstructive pulmonary disease, studying ways to lower flare-up risk and improve symptom control
  • Eosinophilic esophagitis, focusing on reducing inflammation and swallowing problems
  • Chronic spontaneous urticaria and other inflammatory skin-related conditions, evaluating relief of persistent symptoms

Across these areas, the site is testing new biologic and targeted approaches to improve everyday disease management and reduce the impact of long-term inflammation.

Cardiovascular, Metabolic, and Rare Disease Studies

Research also extends into cardiovascular diseases, congenital and hereditary conditions, and other complex disorders, including studies of both prevention and treatment effectiveness.

  • Atherosclerotic cardiovascular disease and broader cardiovascular disease, with trials focused on lowering risk of major heart and vascular events
  • Low-cardiac output syndrome, evaluating support strategies around cardiac surgery
  • Haemophilia A, studying long-term prevention of bleeding episodes
  • Von-Hippel Lindau disease and decompensated cirrhosis, where research explores diagnostic, theranostic, and supportive treatment options

These trials aim to improve detection, prevention, and symptom management in conditions where careful long-term care can make a major difference for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Largo Citta' D'ippocrate 184131 SalernoItaly
Recruiting now
28 trials
Conditions studied
48

More sites in SalernoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

68 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Novartis Pharma AG

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study of Emrusolmin Safety and Effectiveness in Adults with Multiple System Atrophy, a Brain and Nerve Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Emrusolmin
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.